id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2011-N-0411-0003,FDA,FDA-2011-N-0411,"Withdrawal of Approval of 70 New Drug Applications and 97 Abbreviated New Drug Applications: Bristol-Myers Squibb Co., et al.; Correction",Notice,Correction,2011-12-22T05:00:00Z,2011,12,,,2011-12-22T17:07:37Z,2011-32822,0,0,0900006480f87d1a
FDA-2011-N-0411-0002,FDA,FDA-2011-N-0411,"Wyeth Pharmaceuticals, Inc., to FDA/CDER Office of Generic Drugs, July 5, 2011 - Letter",Other,Letter(s),2011-08-16T04:00:00Z,2011,8,2011-08-16T04:00:00Z,,2011-08-16T16:23:03Z,,0,0,0900006480ebaca3
FDA-2011-N-0411-0001,FDA,FDA-2011-N-0411,Withdrawal of Approval of 70 New Drug Applications and 97 Abbreviated New Drug Applications: Bristol-Myers Squibb Co. et al.,Notice,NWL-Notice of Withdrawl,2011-06-08T04:00:00Z,2011,6,,,2011-06-08T16:54:42Z,2011-14164,0,0,0900006480e400da